Blood Disorders & Hematology Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

This Phase 3 trial from the University of Leeds is exploring personalized immunotherapy for patients with multiple myeloma who cannot undergo transplant. By tailoring treatment based on how patients initially respond and their overall fitness, the study aims to find more effective and better tolerated options. This approach could lead to improved outcomes for people managing this challenging blood cancer.

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This Phase 2 trial by the National Cancer Institute is testing if adding nivolumab to blinatumomab can improve treatment for children and young adults experiencing their first relapse of B-cell acute lymphoblastic leukemia. Including patients with Down syndrome, the study looks at whether the combination can boost the immune system’s ability to fight cancer and increase remission rates. The results may expand treatment options with manageable side effects in this vulnerable group.

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Conducted by St. Jude Children's Research Hospital, this Phase 2 trial is testing new targeted and immunotherapy treatments for children newly diagnosed with acute lymphoblastic leukemia or lymphoma. The study seeks to improve survival and reduce side effects by adjusting therapy based on genetic features and early treatment response. Though not currently recruiting, this trial promises important insights for more precise and kinder treatments in pediatric blood cancers.

Uganda Sickle Surveillance Study (US-3)

This observational study in Uganda is examining how common sickle cell trait and disease are among children. Understanding the prevalence of sickle cell disease helps healthcare providers and communities better plan care and support for affected children. By recruiting a large number of participants, this study aims to map the burden of sickle cell disease in the region, which could lead to improved health services and awareness.

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

This study offers access to axicabtagene ciloleucel, a cell therapy for patients with certain lymphomas who cannot use standard commercial products. Sponsored by Kite, a Gilead company, the study provides treatment options for those with large B-cell or follicular lymphoma when other therapies are not suitable. Availability at multiple sites in the US and Japan helps more patients receive this advanced therapy.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.